

ADULT CYSTIC FIBROSIS CONFERENCE

1-2 December 2023 | Milan, Italy

PROGRAMME



OVERVIEW PROGRAMME


 **LIVE** Live streaming session

FRIDAY, 1.12.2023

Rooms


Aula Magna	Aula 111	Aula 113	Aula Malliani
------------	----------	----------	---------------

10:00-12:00

SYMPOSIUM
Opening session: Horizon 2030 for CF care
 **LIVE**

12:00-13:30 Lunch Break

13:30-15:00

SYMPOSIUM
CF Diagnosis in Children and Adults
 **LIVE**


15:00-15:15 Break

15:15-16:35

PRO AND CON DEBATE
Therapy and management of CF patients: The changing landscape with CFTR-modulators
 **LIVE**

16:35-17:00 Coffee Break

17:00-18:30

SYMPOSIUM
Considering future health beyond the lungs
 **LIVE**



18:30-19:15 Welcome Reception

OVERVIEW PROGRAMME

 **Live streaming session**

SATURDAY, 2.12.2023

Rooms

Aula Magna	Aula 111	Aula 113	Aula Malliani
9:00-10:30			
SYMPOSIUM Infections and inflammation in CF 			
10:30-11:00 Coffee Break			
11:00-12:00			
ORAL PRESENTATION Interactions with other conditions/infections	ORAL PRESENTATION Diagnostics and treatment	ORAL PRESENTATION Treatment and management (2)	ORAL PRESENTATION Treatment and management (1)
12:00-13:30 Lunch Break			
13:30-14:30			
MEET THE EXPERTS Fertility and Parenthood	MEET THE EXPERTS What makes a good CF centre?		
14:30-14:45 Coffee Break			
14:45-15:45			
CASE-BASED SESSION Challenging clinical cases	CASE-BASED SESSION Advances in cystic fibrosis diagnosis and management	CASE-BASED SESSION Innovative therapies and insights in cystic fibrosis care	ORAL PRESENTATION Management, transition and reproductive health
15:45-17:15			
SYMPOSIUM Challenges in management of CF from childhood to advanced disease 			

☰ PROGRAMME

10:00 - 12:00

Symposium: Opening session: Horizon 2030 for CF care**Aims :** To put in context new challenges for CF care**Target audience :** Clinician, Educationalist, Fellow, General practitioner, Lung function technician, Microbiologist, Pulmonologist, Researcher, Respiratory physician, Respiratory therapist, Scientist**Chairs :** Francesco Blasi (Milan, Italy), Mirjam Stahl (Berlin, Germany)**10:00 University of Milan - Rettore's address**
Speaker to be confirmed**10:10 Introduction - CF Conference**
Francesco Blasi (Milan, Italy), Eva Polverino (Barcelona, Spain)**10:20 New drugs new challenges in cystic fibrosis care**
Isabelle Fajac (Paris, France)**10:45 Dealing with modulator non-responsive mutations**
Cornelis Kors van der Ent (Utrecht, Netherlands)**11:10 What do people with CF think?**
Alan Smyth (Nottingham (Nottinghamshire), United Kingdom), Speaker to be confirmed**11:45 Discussion and Q&A**

13:30 - 15:00

Symposium: CF Diagnosis in Children and Adults**Aims :** To learn about similarities and differences of CF-diagnosis in the various age groups; to gain knowledge about the optimization of newborn screening; to get to know peculiarities of early diagnosis; to gain knowledge about CF diagnosis in the adults; to become familiar with various biomarkers helping to diagnose CFTR-related disorders**Chairs :** Silke Van Koningsbruggen-Rietschel (Köln, Germany), Carlo Castellani (Genoa, Italy)**13:30 Screening optimization and early diagnosis: where are we?**
Kevin Southern (Liverpool (Merseyside), United Kingdom)**13:55 Adults and CF: from clues to diagnosis**
Andrea Gramegna (Milano (MI), Italy)**14:20 Biomarkers can help in the diagnosis of CFTR-related disorders**
Pierre-Régis Burgel (Paris, France)**14:45 Discussion and Q&A**

15:15 - 16:35

Pro and con debate: Therapy and management of CF patients: The changing landscape with CFTR-modulators**Aims :** To understand the changing landscape with CFTR modulators; to gain knowledge about the PROs and CONs for stopping symptomatic pulmonary therapies; to become familiar with potential future models of CF care.**Chairs :** Silke Van Koningsbruggen-Rietschel (Köln, Germany), Chair to be confirmed**15:15 Better outcomes with CFTR-modulators - Stopping symptomatic pulmonary therapies is justified - PRO**
Gwyneth Davies (London, United Kingdom)**15:25 Better outcomes with CFTR-modulators - Stopping symptomatic pulmonary therapies is justified - CON**
Dorota Sands (Warszawa, Poland)**15:35 PRO/CON Discussion**
Gwyneth Davies (London, United Kingdom), Dorota Sands (Warszawa, Poland)**15:55 What is the future model for CF care? CF care should still take place in CF centres - PRO**
Carlo Castellani (Genoa, Italy)**16:05 What is the future model for CF care? CF care should still take place in CF centres - CON**
Scott Bell (Brisbane (QLD), Australia)

16:15 **PRO/CON Discussion**
Carlo Castellani (Genoa, Italy), Scott Bell (Brisbane (QLD), Australia)

17:00 - 18:30

Symposium: Considering future health beyond the lungs

Aims : Describe the evolving complications across multi organs/ systems

To describe and propose clinical monitoring to address the new complications

To propose the changes in practices to reduce risk or manage the new complications in clinical practice

Target audience : Allied health professional, Clinician, Fellow, Immunologist, Junior member, Nurse, Oncologist, Physiotherapist, Pulmonologist, Respiratory physician, Respiratory therapist

Chairs : Francesco Blasi (Milan, Italy), Chris Smith (BRIGHTON, United Kingdom)

17:00 **Diabetes and diet: How to manage the adult**
Sarah Collins (London, United Kingdom)

17:20 **Cardiovascular risk: a new issue for CF adult patients?**
Barry Plant (Cork, Ireland)

17:40 **Cancer: screening, biomarkers and risk factors**
Patrick Maisonneuve (, Italy)

18:00 **Impact of longer life: Holistic care for the older adult**
Nicholas Simmonds (London, United Kingdom)

18:20 **Discussion and Q&A**

18:30 - 19:15

Welcome Reception: Welcome Reception

09:00 - 10:30

Symposium: Infections and inflammation in CF

Aims : After this session, the auditorium has gained insights into inflammation in CF lung disease starting soon after birth and the problems with treating this aspect of CF. Furthermore, the role of antimicrobial therapy, especially in the era of highly effective CFTR modulator therapy, will be discussed. In addition, lessons that can be learned from the treatment of the heterogenous group of people with non-CF bronchiectasis will be presented to stimulate transfer of knowledge to CF, where bronchiectasis is as a hallmark of lung disease.

Target audience : Clinician, Fellow, General practitioner, Immunologist, Junior member, Microbiologist, Paediatrician, Researcher, Resident, Scientist

Chairs : Mirjam Stahl (Berlin, Germany), Scott Bell (Brisbane (QLD), Australia)

09:00 Inflammation in infants with CF: Origin of a life-long problem
Mirjam Stahl (Berlin, Germany)

09:20 Why don't anti-inflammatories work in CF?
Nicholas Simmonds (London, United Kingdom)

09:40 Changing profile of infection and microbiome in CF: When to use antibiotics in the era of HEMT
Stephanie Thee (Berlin, Germany)

10:00 Lessons from Bronchiectasis not caused by CF
James D. Chalmers (Dundee (Angus), United Kingdom)

10:20 Discussion and Q&A

11:00 - 12:00

Oral presentation: Interactions with other conditions/infections

Chairs : Chair to be confirmed

Middle east respiratory syndrome (MERS) and novel coronavirus disease-2019 (COVID-19) from causes to preventions in Saudi Arabia
Mohammad Hussain Alyami (Najran, Saudi Arabia)

Respiratory infections of upper and lower airways in patients with cystic fibrosis.
Daniela Dolce (Firenze, Italy), Cristina Fevola, Silvia Campana, Novella Ravenni, Chiara Bianchimani, Giulia Santini, Michela Francalanci, Maria Chiara Cavicchi, Valeria Galici, Anna Silvia Neri, Vito Terlizzi, Diletta Innocenti, Eleonora Masi, Beatrice Ferrari, Chiara Castellani, Matteo Masolini, Erica Camera, Tommaso Orioli, Silvia Bresci, Beatrice Borch, Annalisa Cavallo, Jessica Mencarini, Giovanni Taccetti

Cervical cancer in cystic fibrosis: from treatment to prevention
Susan Parker (nnnn, United Kingdom), Aleksandra Duffy, Alan Anderson, Stephen Bourke

Serological antibody response to COVID-19 mRNA vaccination in adults with Cystic Fibrosis
Uclan K. Flanders (Maastricht (LI), Netherlands), Ianthe Piscaer, Julia Olislagers, Marijke Rutten, Geertjan Wesseling, Frits Franssen, Lennart Conemans

Effect of Inhaled Corticosteroid Use on Covid-19 Pneumonia severity and mortality
Hatice Kılıç (Ankara, Turkey), Emre Altın, Emine Argüder, Habibe Hezer, Ebru Sengül Seref Parlak, Yasin Kocaman, Mükrem Er, Aynil Dalkıran, Hülya Çelenk Ergüden, Aysegül Karalezli, Hatice Canan Hasanoğlu, Ebru Ünsal, Aziz Ahmet Süre, Rahmet Güner, Imran Hasanoğlu, Zeynep Hancıoğlu, Emin Gemcioğlu, Musa Civak, Sibel Günay, Esmehan Akpınar, Ayşe Kaya Kalem, Bircan Kayaaslan, Filiz Sadi Aykan, Fatma Eser, Adalet Aypak, Selma Karaahmetoglu, Osman Inan, Abdurrezzak Yılmaz, Serhat Hayme, Esra Çopuroglu, Ihsan Ates, Emre Demir, Isıl Kocak Turan, Bagdagul Yuksel Guler, Emra Asfuroglu Kalkan

First case of pott's disease in a cystic fibrosis adolescent with a homozygous CFTR mutation c.3700 A > G (p. Ile1234Val)
Nadine Asir (Doha, Qatar), Noor Al-Sulaiti, Abdusamea Shabani, Atqah Abdul Wahab

COVID-19 vaccine and morbidity in the Adult Cystic Fibrosis Centre in Institute for Pulmonary Diseases of Vojvodina Sremska Kamenica, Serbia
Dusan Škrbic (Novi Sad, Republic of Serbia), Mirna Djuric, Jelena Papovic, Branislav Tusek

Uptake of retinal screening in patients with cystic fibrosis diabetes in a single adult cystic fibrosis centre
Matthew Birss (Fleet, United Kingdom), Davina Jugnarain, Josie Cunningham, Chris Orchard

Rising Trends in Pseudomonas aeruginosa and MRSA Isolations in CF patients: A 5-Year Retrospective Analysis from CF center
Filip Doksimovski (Skopje, North Macedonia), Elena Ginovska-Tasevska, Ivana Arnaudova-Danevska, Tatjana Jakjovska

11:00 - 12:00

Oral presentation: Diagnostics and treatment

Chairs : Isabelle Fajac (Paris, France), Chair to be confirmed

Late diagnosed homozygous delF508 patients - is it really rare?

Guergana Petrova (Sofia, Bulgaria), Mila Baycheva, Dimitrinka Miteva, Vera Papochieva, Margarita Nikolova, Miglena Georgieva, Nadezhda Yaneva, Savov Alexey

CF diagnosed at the sixth decade of life

Guergana Petrova (Sofia, Bulgaria), Nadezhda Yaneva, Alexey Savov

Exploring the knowledge of genetics laboratories on CFTR modulator therapy eligibility: findings and reflections during external quality assessment

Nele Laudus (Leuven, Belgium), Celia Badenas, Heike Torkler, Raina Yamamoto, Marie-Pierre Audrézet, Caroline Raynal, Manuela Seia, Valentina Giannone, Dragica Radojkovic, Elisabeth Mc Dequeker

To treat or not to treat? When CF is a CF

Guergana Petrova (Sofia, Bulgaria), Petko Karagiozov, Todorova Albena, Mila Baycheva

Real-world Elexacaftor/Tezacaftor/Ivacaftor(ETI) changes prospective sputum collection and microbiological reporting in a single centre pilot CF cohort.

Kevin Frederick Deasy (Cork, Ireland), Hisham Ibrahim, Mairead Mc Carthy, Claire Fleming, James Dorgan, Yvonne Mc Carthy, Ciara Howlett, Sarah Twohig, Paul O'Regan, Laura Kirwan, Desmond M Murphy, Barry J Plant

Clinical, radiological and systemic inflammatory outcomes in real-world Kaftrio study (CORK2) in CF patients homozygous for Phe508del mutation.

HISHAM I S IBRAHIM (Cork, Ireland), Kevin Deasy, Alexander T O'Mahony, Mairead Mccarthy, James Dorgan, Claire Fleming, Ciara Howlett, Yvonne Mccarthy, Sarah Twohig, Paul O'Regan, Laura Kirwan, Michael M Maher, Owen J O'Connor, Barry J Plant

A case of cystic fibrosis diagnosed at twenty years old

Meltem Yilmaz (Tekirdağ, Turkey), Levent Mutlu

Initial experiences in treatment with modulatory therapy in patients with Cystic Fibrosis in North Macedonia

Sonja Momchilovikj (Skopje, North Macedonia), Dejan Dokic, Sava Pejkovska, Smiljko Jovanoski, Dimitar Karkinski, Zoran Arsovski, Stojka Naceva-Fustik, Andrijana Andreevska-Stepanovska, Valentina Cvejaska Cholakovska, Lidija Spirevska, Irina Lucheska

Even grandparents can be diagnosed with Cystic Fibrosis!

Giulia Orpheu (Chieri, Italy), Stefania Patrino, Marta Saporito, Erica Falzone, Nausicaa Scopelliti, Luca Riberi, Andrea Falco, Sonia Moi, Sara Demichelis, Alberto Perboni, Barbara Messori, Letizia Valsecchi

Is there a role for sweat chloride levels as a marker of clinical response to Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis patients?

Rudi Mauro Pereira Fernandes (Lisboa, Portugal), Elsa Fragoso, Carlos Lopes, Pilar Azevedo

11:00 - 12:00

Oral presentation: Treatment and management (2)

Chairs : James D. Chalmers (Dundee (Angus), United Kingdom), Sarah Collins (London, United Kingdom)

CFTR Modulator Therapy Rescues CFTR and Lowers P2X7R-induced Inflammasome Activation of Airway Epithelial Cells

Debananda Gogoi (Dublin, Ireland), Michelle Casey, Caoimhe Bolger, Sabrina Alghamdi, Parisa Acquilini, Lorraine D'Costa, Rory Baird, Olive McCabe, Cedric Gunaratnam, Noel G Mcelvaney, Claudie Gabillard-Lefort, Emer Reeves

Patients not eligible for CFTR-modulators (CFTRm) in Europe: characteristics and distribution

Irene Tomarelli (milano, Italy), Claudia De Petro, Annalisa Orienti, Luigi Annicchiarico, Sofia Misuraca, Martina Contarini, Andrea Gramegna, Francesco Blasi

The Neuropsychiatric Implications of CFTR Modulator Therapy in Cystic Fibrosis Patients: A Systematic Review and Analysis of Regulatory Data

Jacob O'Connor (Birkenhead, United Kingdom)

A 5-year monocentric retrospective analysis of the use of Ceftazidim/Avibactam and Ceftolozane/Tazobactam in adult cystic fibrosis patients

Till Othmer (Berlin - Friedenau, Germany), Marcus Mall, Stephanie Thee, Mirjam Stahl

Bacteriophage therapy in cystic fibrosis patients - a comprehensive analysis of the outcomes and statistics at the Eliava Phage Therapy Center
Mariam Dadiani (Tbilisi, Georgia), Lia Nadareishvili, Nata Nakaidze, Deia Nizharadze, Mzia Kutateladze

HETEROGENEITY IN TREATMENT RESPONSE TO ELEXACAFITOR-TEZACAFITOR-IVACAFITOR IN PEOPLE WITH CYSTIC FIBROSIS
Federica Bellino (Milano, Italy), Gianfranco Alicandro, Andrea Gramegna, Enrica Nazzari, Calogero Sciarabba, Valeria Dacco', Francesco Blasi

Outcomes of short-term modulatory therapy in adult cystic fibrosis
Oğuz Karcioglu (Ankara, Turkey), Aytekin Idikut, Ebru Damadoğlu

Pulmonary exacerbation rates after three years of Elexacaftor/Tezacaftor/Ivacaftor therapy in adults with cystic fibrosis and severe lung disease
Daniela Savi (Rome, Italy), Francesca Lucca, Gloria Tridello, Sara Tomezzoli, Monica Signorini, Giulia Cucchetto, Marisol Ocampo Barao, Marco Cipolli

Long-term effectiveness and safety of Elexacaftor/Tezacaftor/Ivacaftor in daily practice of a Portuguese Cystic Fibrosis Reference Centre
Rudi Mauro Pereira Fernandes (Lisboa, Portugal), Elsa Fragoso, Carlos Lopes, Pilar Azevedo

Effect of elexacaftor/tezacaftor/ivacaftor on body plethysmography measurements in patients with cystic fibrosis and advanced lung disease.
Chiara Premuda (Milano, Italy), Andrea Gramegna, Gianfranco Alicandro, Francesca Lucca, Mariangela Retucci, Sonia Volpi, Marco Cipolli, Francesco Blasi

11:00 - 12:00

Oral presentation: Treatment and management (1)

Chairs : Pierre-Régis Burgel (Paris, France), Chair to be confirmed

Predictive factors for weight gain after initiation of elexacaftor/tezacaftor/ivacaftor among people with cystic fibrosis
Gloria Leonardi (Trento, Italy), Andrea Gramegna, Fabio Majo, Luca Cristiani, Francesco Amati, Martina Contarini, Stefano Aliberti, Alessandro Giovanni Fiochi, Francesco Blasi

Decreased mucolytic prescriptions in Phe508del homozygous Cystic Fibrosis adults on Elexacaftor-tezacaftor-ivacaftor
Mohammed Azib Zahid (LONDON, United Kingdom), James Hartley, Akangsha Sur Roy, Clare Lau, Frederick Jarvis, Komal Mukhtar, Malik Khan

An “expanding area” of interest- The effect of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on body image and weight
Anna Scholz (Cardiff, United Kingdom), Cendl Xanthe, Gareth Hall, Anna Mcculloch, Rhiannon Phillips, David Proud, Lorraine Speight, Jamie Duckers

Changes in nutritional status and muscular strength in adult patients with cystic fibrosis (pwCF) treated with elexacaftor/tezacaftor/ivacaftor (ETI)
Cecilia Brignole (Verona, Italy), Chiara Cimbalo, Silvia Rigon, Francesca Lucca, Gloria Tridello, Giulia Paiola, Sara Tomezzoli, Sonia Volpi, Marco Cipolli

Elexacaftor/Tezacaftor/Ivacaftor for adult cystic fibrosis patients with preserved lung function: a case series
ZISIS BALMPOUZIS (Lausanne, Switzerland), Georgia Mitropoulou, Alain Sauty, Angela Koutsokera

Side-effects and ETI-treatment: a multidisciplinary challenge
Nele Duplacie (Leuven, Belgium), Trudy Havermans, Janne Houben, Marianne Schulte, Linda Boulanger, Laura Moyens, Cindy Ruelens, Lieven Dupont

Assessing and improving patient knowledge gaps relating to the administration of elexacaftor/tezacaftor/ivacaftor in an adult cystic fibrosis clinic population
Joshua Sill (Norfolk, United States), Benjamin Chilampath, Matthew Bernens, Patricia Banks, Samuel Stein

Plasma concentrations of elexacaftor, tezacaftor and ivacaftor in adult people with cystic fibrosis: A pilot study
Adrienn Banki (Huddinge, Sweden), T. Pincikova

Changes in the cardiometabolic risk factors post elexacaftor-tezacaftor-ivacaftor therapy; a real-world prospective single center study.
HISHAM I S IBRAHIM (Cork, Ireland), Noreen Tagney, Mairead Mccarthy, James Dorgan, Claire Fleming, Ciara Howlett, Karen Cronin, Edel O'Riordan, Janice Mansfield, Sarah Twohig, Tamara Vagg, Deasy Kevin, Barry J Plant

A patient journey from lumacaftor/ivacaftor (LI) to tezacaftor/ivacaftor (TI) to elexacaftor/tezacaftor/ivacaftor (ETI): a single center case series

Noreen Tangney (Killarney, Ireland), Tamara Vagg, Kevin Deasy, Mairead Mccarthy, James Dorgan, Claire Fleming, Ciara Howlett, Karen Cronin, Edel O'Riordan, Janice Mansfield, Sarah Twohig, Hisham Ibrahim, Barry J Plant

13:30 - 14:30

Meet the Experts: What makes a good CF centre?

Aims : Organisation of a CF centre: structure of outpatient clinic and ward; what disciplines are needed; schedule of visits; annual check-ups.

Role of data in CF care: use of patient registries; evidence vs. eminence.

Target audience : Clinician, Fellow, General practitioner, Junior member, Lung function technician, Microbiologist, Nurse, Paediatrician, Physiotherapist, Psychologist, Pulmonologist, Radiologist, Resident, Respiratory physician, Respiratory therapist, Social worker, Student, Trainee

Chairs : Mirjam Stahl (Berlin, Germany), Eva Polverino (Barcelona, Spain)

13:30 Organisation of a CF centre
Clémence Martin (Paris, France)

13:45 Role of data in CF care
Ruth Keogh (London, United Kingdom)

14:00 Discussion

13:30 - 14:30

Meet the Experts: Fertility and Parenthood

Aims : Learn about improved female fertility with HEMT (how to tell the patient that contraception is possibly needed under HEMT) and the increased number of mothers with CF that are in better shape.

Discuss with us what to suggest your female and male patients on how to organize their daily life with a child / several children and their own therapy.

Gain insights into the possibility of treating your unborn child with CF before birth.

Patient perspective from a patient representative to give insights into this topic.

Target audience : Clinician, Fellow, General practitioner, Junior member, Neonatologist, Nurse, Paediatrician, Patient, Psychologist, Pulmonologist, Researcher, Resident, Scientist, Social worker, Student, Trainee

Chairs : Silke Van Koningsbruggen-Rietschel (Köln, Germany)

13:30 Fertility and parenthood
Michal Shteinberg (Haifa, Israel), Imogen Felton (London, United Kingdom)

13:45 Patient perspective

14:00 Discussion

14:45 - 15:45

Case-based session: Challenging clinical cases

Chairs : Barry Plant (Cork, Ireland), Chair to be confirmed

14:45 Eosinophilic pleural effusion in a young patient
Guido Levi (Bovezzo, Italy)

14:50 Q&A

14:55 Multiple osteolytic lesions and generalized lymphadenopathy: a diagnostic challenge
Lakshani Wasana Hakmana Kodithuwakku (Kadawatha, Sri Lanka)

15:00 Q&A

15:05 Diagnostic and therapeutic dilemmas in the management of granulomatous disease in an immunocompromised patient
ALEXANDROS PATSOURAS (Pireus, Greece)

15:10 Q&A

15:15 An unusual case of bronchial asthma
Muhammad Arif (AL AIN, United Arab Emirates)

15:20 Q&A

15:25 **A treatable chILD related to contiguous genes disease**
Sergio Ghirardo (Trieste, Italy)

15:30 Q&A

15:35 **Late diagnosis of cystic fibrosis due to already diagnosed other infectious lung disease**
Tijana Debeljak Cvok (Belgrade, Republic of Serbia)

15:40 Q&A

14:45 - 15:45

Case-based session: Advances in cystic fibrosis diagnosis and management

Chairs : Arietta Spinou (London, United Kingdom), Chair to be confirmed

14:45 **Secondary amyloidosis in cystic fibrosis**
HALİME MUALLA NİZAM (PENDİK, Turkey)

14:50 Q&A

14:55 **The clinical impact of utilising different paediatric reference equations for cardiopulmonary exercise testing**
Karl Sylvester (Cambridge (Cambridgeshire), United Kingdom)

15:00 Q&A

15:05 **A cystic fibrosis case with the p.Phe508del mutation diagnosed in Vietnam: Is it rare in Southeast Asia?**
Pham Ha Giang Cao (HCMC, Vietnam)

15:10 Q&A

15:15 **Intentional lung transplantation due to ABO incompatibility in a cystic fibrosis patient – Case report**
Leidy Prada (BOGOTA, D.C., Colombia)

15:20 Q&A

15:25 **Hyperglycemia and somnolence in CF**
Zulfiya Syunyaeva (Berlin, Germany)

15:30 Q&A

15:35 **Physiotherapy interventions during and after two pregnancies in a CF patient with severe low lung function**
Emma Roberts (Stockholm, Sweden)

15:40 Q&A

14:45 - 15:45

Case-based session: Innovative therapies and insights in cystic fibrosis care

Chairs : Chair to be confirmed

14:45 **Gradual introduction of elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and hepatic impairment using clinical- and therapeutic drug monitoring: a case series**
Steffie Vonk (Amsterdam, Netherlands)

14:50 Q&A

15:00 **Acute ototoxicity in CF patient secondary to macrolide treatment for MAC**
Moshe Heching (Raanana, Israel)

15:05 Q&A

15:15 **CFTR modulator therapy for Cystic Fibrosis in Guatemala**
Luisa Fernanda Martinez Valdeavellano (Guatemala, Guatemala)

15:20 Q&A

15:30 **A case of ECMO: Bridge to decision and recovery in CF acute respiratory failure in the era of highly effective modulator therapy**
Michelle Casey (Dublin 4, Ireland)

15:35 **Q&A**

14:45 - 15:45

Oral presentation: Management, transition and reproductive health

Chairs : Imogen Felton (London, United Kingdom), Scott Bell (Brisbane (QLD), Australia)

Evaluation of post-transfer clinical conditions of the cystic fibrosis(CF) patients transferred to the adult chest diseases

Hande Yuçe (Ankara, Turkey), Oguz Karcioğlu, Ebru Damadoglu, Ali Fuat Kalyoncu

Adherence to medical regimens after lung transplantation among adults with Cystic Fibrosis increased during COVID-19 pandemic

Ulrika Skogeland (Tullinge, Sweden), Anna Hedborg, Cecilia Rodriguez, Adrienn Bánki, Tove Godsken

Bronchoscopic practices in adult Cystic Fibrosis at Cork University Hospital 2012-2022: Increased usage, new Indications and the emergence of single-use flexible bronchoscopy.

Kevin Frederick Deasy (Cork, Ireland), Hisham Ibrahim, Claire Fleming, Mairead Mc Carthy, James Dorgan, Yvonne Mc Carthy, Sarah Twohig, Paul O'Regan, Laura Kirwan, Michael T Henry, Marcus P Kennedy, Desmond M Murphy, Barry J Plant

The A-Step - a new incremental exercise test defying space and infection control measures

Natascha Remus (Creteil, France), Gaetan Leignadier, Elisa Thomas, Celine Delestrain, Michael Shum, Bernard Maitre, Ralph Epaud, Benoit Douvry

Evolving gender identification within the cystic fibrosis population.

Anna Scholz (Cardiff, United Kingdom), Alice Darby, Amy Hiller, Jamie Duckers, Lorraine Speight

Maternal and obstetric outcomes in women with cystic fibrosis: a retrospective case series of patients in UZ Leuven

Tanne Daniels (Halen, Belgium), Kristel Van Calsteren, Lieven Dupont

Patient satisfaction after transition to adult CF clinic

Moshe Heching (Raana, Israel), Liora Slomiansky, Hannah Blau, Huda Mussaffi, Dario Prais, Joel Weinberg, Mordechai Kramer

Evolution of cystic fibrosis adult population over the last 10-years in Europe

Annalisa Orenti (Milan, Italy), Elpis Hatzigorou, Eitan Kerem, Christiane De Boeck, Pierre-Regis Burgel

Quantitative computed tomography measures of disease severity in cystic fibrosis

Gabrielle Baxter (London, United Kingdom), Ashkan Pakzad, Bojidar Rangelov, Shayan Shaikh, Ying Xin Tan, Robert Chapman, Daniel Peckham, Joseph Jacob

Knowledge, attitudes and behaviors on reproductive health of patients followed at hacettepe university adult cystic fibrosis (CF) center

Hande Yuçe (Ankara, Turkey), Sezcan Mumusoglu, Ali Fuat Kalyoncu, Ebru Damadoglu

Bone health in adults with cystic fibrosis in the Republic of North Macedonia

Tatjana Jakovska-Maretti (Skopje, North Macedonia), Marta Foteva, Ivana Arnaudova Daneva

15:45 - 17:15

Symposium: Challenges in management of CF from childhood to advanced disease

CF transition

Aims : To describe major challenges related to management of CF across different ages and disease stages. This session will highlight the importance of multidisciplinary and holistic approach to a disease that is affecting all aspect of patient' life

Target audience : Allied health professional, Cardiologist, Clinician, Junior member, Lung function technician, Microbiologist, Nurse, Paediatrician, Patient, Physiotherapist, Psychologist, Pulmonologist, Radiologist, Respiratory physician, Respiratory therapist, Social worker, Student, Thoracic surgeon, Trainee

Chairs : Arietta Spinou (London, United Kingdom), Chair to be confirmed

15:45 **Transition of CF patients: what professionals and specialties should be involved?**
Andrea Gramegna (Milano (MI), Italy)

16:05 **Monitoring and prevention in CF across different age classes and disease stages**
Michal Shteinberg (Haifa, Israel)

16:25 **The ageing of CF patients with new modulators**
Eva Polverino (Barcelona, Spain)

16:45 **Mental health in CF patients: impact on disease outcomes and challenges with age.**
Marieke Verkleij (Amsterdam, Netherlands)

17:05 **Discussion and Q&A**
